[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perioperative-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perioperative-complication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,44,67,96,121,149,183,217,244,275,295,320,344,367],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100637976","pneumoperitoneum-pressure-and-lung-ultrasound-atelectasis-100637976",false,"NCT07609615","Pneumoperitoneum Pressure and Lung Ultrasound Atelectasis","Effects of Different Pneumoperitoneum Pressures on Perioperative Atelectasis Assessed by Lung Ultrasound in Laparoscopic Cholecystectomy: A Prospective Randomized Single-Blind Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years\n* ASA physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy under general anesthesia\n* Body mass index (BMI) \\\u003C30 kg\u002Fm²\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Chronic pulmonary disease\n* Recent respiratory tract infection\n* Thoracic deformity or previous thoracic surgery\n* Preoperative pulmonary pathology\n* Morbid obesity\n* Pregnancy\n* Emergency surgery\n* Conversion to open surgery\n* Requirement for protocol-violating pneumoperitoneum pressure modification\n* Refusal to participate in the study","ALL","18 Years","65 Years",{"count":20,"type":21},112,"ESTIMATED","INTERVENTIONAL",[24],"NA","Elective laparoscopic cholecystectomy may lead to perioperative atelectasis due to pneumoperitoneum-related diaphragmatic elevation and impaired respiratory mechanics. Lung ultrasound (LUS) provides a noninvasive bedside method for evaluating perioperative aeration loss. This prospective randomized controlled study aims to compare the effects of low-pressure (10 mmHg) and standard-pressure (14 mmHg) pneumoperitoneum on perioperative atelectasis assessed by LUS in patients undergoing laparoscopic cholecystectomy under general anesthesia. Changes in LUS scores, respiratory mechanics, oxygenation, and postoperative clinical outcomes will also be evaluated.",[27,28,29],"Atelectasis","Perioperative Complication","Pneumoperitoneum",[27,29,28],"RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2026-06-01",{"date":39,"type":21},"2026-09-01",{"name":41,"class":42},"Engin Çetin","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100612111","perioperative-complications-after-neoadjuvant-radiotherapy-for-colorectal-cancer-100612111","NCT07249333","Perioperative Complications After Neoadjuvant Radiotherapy for Colorectal Cancer","Effect of Neoadjuvant Radiotherapy on the Incidence of Perioperative Complications After Radical Surgical Treatment of Colorectal Cancer","Inclusion Criteria:\n\n* Adult patients (over 18 years of age)\n* Clinical Frailty Scale 2, 3 or 4 status\n* Patients undergoing radical surgical treatment of colorectal cancer\n\nExclusion Criteria:\n\n* Patients undergoing palliative surgical treatment of colorectal cancer",{"count":52,"type":21},80,"OBSERVATIONAL","Neoadjuvant radiotherapy plays an important role in the treatment of locally advanced colorectal cancer. Although radiation therapy is extremely important in reducing the tumor mass, downstaging, and therefore providing conditions for curative surgery, neoadjuvant therapy can increase the risk of perioperative complications, which can lead to slower patient recovery, greater perioperative morbidity, prolonged hospitalization, and increased treatment costs.\n\nThe aim of the study is to determine whether there is a difference in the incidence of perioperative complications after radical colorectal cancer surgery between patients who received neoadjuvant radiotherapy and those patients who did not undergo neoadjuvant radiation.\n\nData is collected from the medical documentation and information system of the Oncology Institute of Vojvodina. Demographic characteristics of patients, comorbidities, length of hospital stay, length of treatment in the intensive care unit, occurrence of complications in the perioperative period, as well as data on neoadjuvant therapy are analyzed. All included patients are of similar general condition, as determined by the CFS (Clinical Frailty Scale). Intraoperative complications are graded using the ClassIntra classification of intraoperative adverse events, and the presence of postoperative adverse events are assessed and classified using the Clavien-Dindo classification of postoperative complications and the HARM (HospitAl stay, Readmission, Mortality rate) score.",[56,57,28],"Colorectal Cancer","Neoadjuvant Radiotherapy","2025-11-18",{"date":60,"type":35},"2025-11-25",{"date":62,"type":35},"2024-06-18",{"date":64,"type":21},"2026-06",{"name":66,"class":42},"Oncology Institute of Vojvodina",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100496007","the-hypotension-prediction-index-in-free-flap-transplant-in-head-and-neck-surgery-100496007","NCT05738603","The Hypotension Prediction Index in Free Flap Transplant in Head and Neck Surgery.","The Hypotension Prediction Index in Free Flap Transplant in Head and Neck Surgery - a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients qualified to head and neck free flap surgery\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years\n* Lack of health insurance\n* Pregnancy\n* Known history of congenital heart disease, severe aortic and\u002For mitral stenosis, heart failure and ejection fraction \\\u003C 35 %\n* Persistent atrial fibrillation and other arrhythmias impairing arterial pressure-based cardiac output (APCO) monitoring",{"count":75,"type":21},206,[24],"The aim of the current study is to evaluate the effects of the Hypotension Prediction Index (HPI) on the degree of intraoperative hypotension in patients undergoing free flap surgery. The hypothesis is that implementation of the HPI algorithm will reduce the time-weighted average (TWA) intraoperative hypotension below a threshold of 65 mmHg (16), and to reveal the relationship between the episodes of hypotension and free flap viability and function.",[79,80,28,81],"Hypotension","Head and Neck Cancer","Postoperative Complications",[79,83,84,80,85],"Hypotension Prediction Index","Free Flap Transplant","Perioperative Complications","2025-07-30",{"date":88,"type":35},"2025-08-03",{"date":90,"type":35},"2024-09-01",{"date":92,"type":21},"2026-12",{"name":94,"class":95},"Jakub Szrama","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":43},"100359023","exercise-in-patients-undergoing-urologic-surgery-100359023","NCT03954678","Exercise in Patients Undergoing Urologic Surgery","Prospective Randomized Study of Exercise in Patients Undergoing Urologic Surgery","Inclusion Criteria:\n\n* Patients scheduled for operative procedure with an inpatient postoperative stay are eligible for this study\n* Patients willing and able to give blood sample as part of standard of care labs\n* Patients willing and able to fill out questionnaire\n* Patients who will fill out the step log daily\n* Patients willing and able to sign informed consent\n\nExclusion Criteria:\n\n* None",{"count":104,"type":21},400,[24],"Patients who are being scheduled for an operative procedure with an inpatient postoperative stay are eligible for this study. Participants will be selected to start a physical fitness plan or a nutrition plan at the time of surgical scheduling. Each participant will be asked to continue their current lifestyle for two days after their pre-operative appointment to get a baseline of activity (by pedometer and functional tests) and nutritional risk (by questionnaire). After two days, patients in the activity group will start their activity plans. They will be encouraged to get 10,000 steps per day and to perform whole body strength training exercises 3 times a week. Five days before and after surgery, participants in the nutrition group will be asked to consume a standard liquid nutrition supplement (i.e. Boost or Ensure) two times per day. Participants in the activity group will record steps and number of strength training sessions completed, while patients in the nutrition group will record the number of supplements consumed.",[28],[109,110,111],"Exercise","Nutrition supplement","Surgery","2025-07-18",{"date":114,"type":35},"2025-07-22",{"date":116,"type":35},"2019-07-30",{"date":118,"type":21},"2026-07",{"name":120,"class":95},"Emory University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100568218","perioperative-impact-of-physical-activity-on-short--and-long-term-morbidity-and-mortality-100568218","NCT06678360","Perioperative Impact of Physical Activity on Short- and Long-term Morbidity and Mortality","Perioperative Impact After Non-cardiac Surgery of Physical Activity on Short- and Long-term Morbidity and Mortality","PeriopIPA","Inclusion Criteria:\n\nAdult patients (equal to or over 18 years) undergoing elective non-cardiac surgery at the two study sites, Karolinska University Hospital Solna and Karolinska University Hospital Huddinge\n\nExclusion Criteria:\n\nPatients under the age of 18, transplant, day surgery, acute surgery, anesthesia monitoring, brachy therapy and gamma knife interventions. In case of multiple surgeries, only the first will be included.",{"count":130,"type":21},180000,"Over 300 million surgeries are performed globally every year. Complications after surgery - infections, cardiovascular conditions, postoperative pulmonary complications and renal impairment - affect survival and quality of life.\n\nAge and co-morbidity are unmodifiable factors, contributing to increased risk of these perioperative complications. However, a modifiable risk factor is physical activity. This study aims to test if self reported physical activity is associated to lower risk of perioperative morbidity and mortality.",[133,28,134,135],"General Surgery","Perioperative Medicine","Physical Inactivity",[137,138,139],"MET-scores","Physical activity","Perioperative mortality","2025-06-02",{"date":142,"type":35},"2025-06-06",{"date":144,"type":35},"2024-11-01",{"date":146,"type":21},"2025-12-01",{"name":148,"class":95},"Karolinska Institutet",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":169,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":43},"100537528","phase-3-colchicine-in-patients-at-cardiac-risk-undergoing-major-non-cardiac-surgery-100537528","NCT06279000","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery","Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery: Prospective, Randomized, Double-blinded, Placebo-controlled, Multi-centre Study","COLCAT","Inclusion Criteria:\n\nundergoing major non-cardiac surgery in general anaesthesia will be included. Major non-cardiac surgery is defined as:\n\n* vascular surgery (with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies)\n* intraperitoneal surgery\n* intrathoracic surgery\n* major orthopaedic surgery (spinal surgery or joint replacement surgery)\n* at cardiovascular risk, defined as meeting at least 1 of the following 6 criteria:\n\n  * preoperative n-terminal pro brain natriuretic peptide (NT-proBNP) ≥ 200 ng\u002Fl\n  * history of coronary artery disease\n  * history of peripheral vascular disease\n  * history of stroke\n  * undergoing major vascular surgery, with the exception of arteriovenous shunt, vein stripping procedures and carotid endarterectomies\n  * fulfilment of any 3 of the 8 following criteria:\n\n    * undergoing major surgery (intrathoracic, intraperitoneal or supra-inguinal vascular surgery)\n    * any history of congestive heart failure or history of pulmonary oedema\n    * anamnestic transient ischemic attack (TIA)\n    * diabetes under treatment with either oral antidiabetic agent or insulin\n    * age \\> 70 years\n    * history of hypertension\n    * serum creatinine \\> 175 mumol\u002Fl or calculated creatinine clearance \\< 60 ml\u002Fmin\u002F1.73m2 (cockcroft gault)\n    * history of smoking within 2 years of surgery\n    * planned surgical time ≥ 90 minutes\n    * planned postoperative hospital stay at least 1 night\n\nExclusion Criteria:\n\n* no written consent\n* inclusion in other clinical trial with direct impact on perioperative medication\n* previously reported side effects or reported intolerance from colchicine (e.g., allergic reaction or significant sensitivity to colchicine or an auxiliary substance of the IMP)\n* pregnancy or planned pregnancy and\u002For breast feeding\n* clinically significant history of drug or alcohol abuse within the last year\n* very severe frailty (≥ 8 clinical frailty scale)\n* patient with inflammatory bowel disease (e.g., Morbus Crohn or Colitis ulcerosa)\n* patient taking colchicine for other indications (e.g., familial Mediterranean fever, gout)\n* severe renal impairment (eGFR \\< 30 ml min -1 1.73 m2 -1) or end-stage renal disease with indication for haemodialysis\n* history of solid organ or bone marrow transplantation\n* systemic immune-suppression (medication (steroids \\>30mg cortisol-equivalent per day, tacrolimus etc...) or disease (e.g., myelodysplastic syndrome)\n* severe hepatic impairment with history of cirrhosis\n* chronic active hepatitis or functional disorders defined as alanine aminotransferase greater than three times the upper limit of normal\n* anticipated post-operative administration of CYP3A4 metabolized substances like cyclosporine, ketoconazole, clarithromycin, verapamil, quinidine, diltiazem or ritonavir\n* Any other condition that the investigator would consider a risk to the patient if the latter were to participate in the study.",true,"45 Years",{"count":160,"type":21},880,[162],"PHASE3","Perioperative myocardial injury and major adverse cardiovascular events (MACE) are common causes of morbidity and mortality in patients at increased cardiovascular risk undergoing non-cardiac surgery.\n\nHowever, research in recent years has yielded limited preventive and therapeutic measures for myocardial injury\u002FMACE. Recent studies in patients with chronic and acute coronary artery disease have shown that colchicine administration can reduce the risk of cardiovascular events.\n\nThese encouraging results in non-surgical patients ask for a similar investigation in patients undergoing major non-cardiac surgery. The aim of the proposed study is to investigate the effects of perioperative colchicine administration on the incidence of myocardial injury\u002FMACE.",[165,166,28,167,168],"Cardiovascular Diseases","Cardiovascular Complication","Myocardial Injury","Myocardial Injury After Noncardiac Surgery (MINS)",[170,171,172,173],"Perioperative Cardiovascular Risk","myocardial injury","major adverse cardiac events","colchicine","2025-04-19",{"date":176,"type":35},"2025-04-24",{"date":178,"type":35},"2025-04-20",{"date":180,"type":21},"2029-03-30",{"name":182,"class":95},"Cantonal Hospital of St. Gallen",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":216},"100382220","phase-3-perioperative-respiratory-care-and-outcomes-for-patients-undergoing-high-risk-abdominal-surgery-100382220","NCT04256798","Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery","PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries","PENGUIN","Inclusion Criteria:\n\n* Adults and children aged 10 years or over\n* Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length\n* Written informed consent of patient (signature or a fingerprint)\n\nExclusion Criteria:\n\n* Patients undergoing caesarean section\n* Patients with a documented or suspected allergy to chlorhexidine\n* Patient unable to complete postoperative follow-up (not contactable after discharge)\n* Previous enrolment in PENGUIN within the past 30 days\n* American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)","10 Years","100 Years",{"count":194,"type":21},12942,[162],"PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.\n\nPatients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.",[198,199,200,201,202,81,203,204,205,28,206,207],"Infection","Pneumonia","Surgical Site Infection","Wound Infection","Surgical Wound Infection","Anesthesia","Communicable Disease","Pathologic Processes","Chlorhexidine","Laparotomy","2025-02-18",{"date":210,"type":35},"2025-02-19",{"date":212,"type":35},"2020-11-13",{"date":37,"type":21},{"name":215,"class":95},"University of Birmingham",37,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100429813","post-discharge-after-surgery-virtual-care-with-remote-automated-monitoring-technology-2-pvc-ram-2-trial-100429813","NCT04876950","Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial","PVC-RAM-2","Inclusion Criteria:\n\n1. are ≥40 years of age;\n2. will undergo or have undergone semi-urgent, urgent, or emergency surgery requiring expected hospital stay of ≥2 days; and\n3. provide informed consent to participate.\n\nExclusion Criteria:\n\n1. planned transfer to a rehabilitation or convalescent facility, or repatriation from trial hospital site to local community hospital following surgery;\n2. are unable to communicate with research staff, complete study surveys, or undertake an interview using a tablet computer due to a language barrier or a cognitive, visual, or hearing impairment; or\n3. reside in an area without cellular network coverage.","40 Years",{"count":226,"type":21},2000,[24],"The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology-2 (PVC-RAM-2) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on acute-hospital care during the 45-day follow up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. Secondary outcomes at 45 days after randomization include 1) days in hospital; 2) index length of hospital stay; 3) hospital re-admission; 4) emergency department visit; 5) medication error detection; 6) medication error correction; and 7) surgical site infection. Additional secondary outcomes are pain of any severity, and moderate-to-severe pain assessed at 15 and 45 days. We will also assess optimal management of long-term health by evaluating among self-reported current smokers and those with atherosclerotic disease, whether patients are taking classes of efficacious medications at 45 days post randomization.",[111,28],[231,232,233],"Virtual care","Remote monitoring","Acute hospital care","2024-11-13",{"date":236,"type":35},"2024-11-15",{"date":238,"type":35},"2024-10-04",{"date":240,"type":21},"2026-03",{"name":242,"class":95},"Population Health Research Institute",2,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":252,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":257,"studyType":53,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100566463","enhanced-recovery-protocols-in-gynecologic-oncology-100566463","NCT06655506","Enhanced Recovery Protocols in Gynecologic Oncology","Enhanced Recovery Protocols in Gynecological Cancer Patients: a Feasibility Study","ERGO","Inclusion Criteria:\n\npatients with gynaecological cancer and an ECOG performance status \\\u003C4, ASA score \\\u003C4.\n\nExclusion Criteria:\n\npatients with metastatic cancer of non-gynaecological origin patients that are not able to follow ERAS protocol due to medical reasons patients with severe debilitating comorbidities (ECOG status 4, ASA score 4-5)","FEMALE","25 Years","85 Years",{"count":256,"type":21},600,"60 Days","Enhanced Recovery After Surgery (ERAS) are developed to provide a systematic structure for managing postsurgical patients.These protocols promote evidenced-based practices and implement a multidisciplinary effort to maintain normal physiology in the perioperative period and aid in earlier recovery. The present study aims to investigate the feasibility of and compliance to a structured ERAS protocol among Gynecological Oncological Centers in Greece as well as to compare the outcomes among patients that fullfilled the minimum number of necessary criteria, compared to those that were enrolled in ERAS protocols but did not meet the sufficient necessary criteria.",[260,261,28,262,263,264],"ERAS","Gynecologic Cancer","Postoperative Pain","Quality of Life","Infections","2024-10-22",{"date":267,"type":35},"2024-10-23",{"date":269,"type":35},"2024-10-20",{"date":271,"type":21},"2026-07-30",{"name":273,"class":95},"National and Kapodistrian University of Athens",8,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":43},"100382972","brain-targeted-goal-directed-therapy-in-high-risk-patients-undergoing-major-elective-surgery-the-brain-promise-study-100382972","NCT04266574","BRAIN-targeted Goal-directed Therapy in High-risk Patients undeRgOing Major electIve SurgEry: the BRAIN-PROMISE Study","BRAINPROMISE","Inclusion Criteria:\n\n* hypertensive patients with American Society of Anesthesiologists (ASA) score≥ 2 with either Age ≥ 65 years or frailty score ≥5\n* presence of an arterial catheter during anesthesia\n* planned high-risk surgery (abdominal, vascular, urologic, thoracic one-lung ventilation (OLV) procedures), longer than 60 minutes, in general anesthesia\n* ability to give informed consent according to International Conference on Harmonization ICH\u002F Good Clinical Practice (GCP), and national\u002Flocal regulations\n\nExclusion Criteria:\n\n* Unable to consent to study inclusion\n* Language barrier\n* Severe neurological or psychiatric disease\n* End-stage dementia\n* Total Intravenous anesthesia\n* No use of hypertensive medication at home.",{"count":283,"type":21},200,[24],"The aim of the study is to further understand whether the use of non-invasive monitoring NIRS (Near Infrared Spectroscopy) is useful in reducing postoperative complications in high-risk patients undergoing elective surgery.",[111,28],"2024-10-21",{"date":267,"type":35},{"date":290,"type":35},"2020-11-17",{"date":292,"type":21},"2024-12",{"name":294,"class":95},"Istituto Clinico Humanitas",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":43},"100550346","phase-2-efficacy-and-safety-of-modified-si-jun-zi-tang-in-perioperative-nsclc-treatment-100550346","NCT06445881","Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment","A Multi-center, Prospective, Exploratory Study Evaluating the Efficacy and Safety of a Modified Si Jun Zi Tang Formula in the Perioperative Treatment of Non-small Cell Lung Cancer","MSJZT-NSCLC","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years.\n2. Pathologically confirmed non-small cell lung cancer (NSCLC) with no prior treatment for this tumor.\n3. Clinical stage II-IIIB (N2) tumors assessed as resectable or potentially resectable by a multidisciplinary team (MDT).\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 - 1.\n5. Adequate organ function, including:\n\n   Bone marrow: Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL, platelets ≥ 80 x 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL.\n\n   Liver: Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤ 3 times ULN.\n\n   Kidneys: Creatinine clearance rate ≥ 45 mL\u002Fmin (using the standard Cockcroft-Gault formula) or ≤ 1.5 times ULN.\n6. At least one measurable lesion according to RECIST v1.1 criteria.\n7. For women: Must be surgically sterilized, postmenopausal, or use highly effective contraception during and for 3 months after treatment; must not be pregnant or breastfeeding during the treatment period.\n8. Patients must have compliance and geographic proximity to ensure adequate follow-up.\n\nExclusion Criteria:\n\n1. Patients with a history of autoimmune diseases, active tuberculosis, active hepatitis (HBV DNA \\\u003C2000 IU), or HIV infection.\n2. Patients expected to be unable to tolerate surgery, such as those with severe cardiopulmonary insufficiency or coagulation disorders (APTT \\\u003C1.5 times ULN, INR \\>2.0, PT \\>16 seconds).\n3. History of other malignancies within the past 2 years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin, superficial bladder cancer \\[Ta, Tis \\& T1\\], or papillary thyroid carcinoma.\n4. Any unstable systemic disease (including active systemic infections requiring systemic treatment, liver disease, kidney disease, or metabolic disorders, acute cerebral infarction or cerebral hemorrhage, etc.).\n5. Significant cardiovascular events: congestive heart failure \\> NYHA Class 2; unstable angina, active coronary artery disease (CAD) (myocardial infarction over 1 year before study entry is allowed); severe arrhythmias requiring treatment (use of beta-blockers or digoxin is allowed) or uncontrolled hypertension.\n6. Significant neurological or psychiatric disorders, including epilepsy, dementia, etc.\n7. Patients with interstitial lung disease or a history of interstitial pneumonia.\n8. Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment.\n9. Previous use of PD-1\u002FPD-L1 inhibitors or other anti-tumor immunotherapy drugs.\n10. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or planned transplantation.\n11. Known allergy to the drugs or drug excipients used in the study or severe allergic reactions to other monoclonal antibodies.\n12. Presence of other severe physical or laboratory abnormalities that may increase the risk of participating in the study, interfere with study results, or any other condition that, in the investigator's judgment, may affect the conduct or results of the clinical study.","75 Years",{"count":305,"type":21},60,[307],"PHASE2","Chemotherapy combined with immunotherapy is the current standard perioperative treatment for non-small cell lung cancer (NSCLC). However, this regimen has multiple side effects and shows variable efficacy among individuals. In China, adjunctive traditional Chinese medicine is widely accepted by lung cancer patients. Modified Si Jun Zi Tang, a classic formula in traditional Chinese medicine, is known for its benefits in unifying and strengthening the spleen. This study aims to evaluate whether the addition of Modified Si Jun Zi Tang to chemotherapy and immunotherapy during the neoadjuvant phase can improve the R0 resection rate, objective response rate (ORR), and safety in patients with resectable and potentially resectable NSCLC. Secondary objectives include assessing whether this combination can improve 1-year and 2-year disease-free survival (DFS) post-surgery. Additionally, we will collect relevant biological samples to identify tumor markers associated with efficacy, prognosis, and side effects, providing a theoretical basis for modernizing and standardizing traditional Chinese medicine.",[310,28],"Non Small Cell Lung Cancer","2024-06-02",{"date":313,"type":35},"2024-06-06",{"date":315,"type":35},"2024-06-01",{"date":317,"type":21},"2026-12-31",{"name":319,"class":95},"First Affiliated Hospital of Zhejiang University",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":53,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":43},"100464701","perioperative-longitudinal-study-of-complications-and-long-term-outcomes-100464701","NCT05331118","Perioperative Longitudinal Study of Complications and Long-term Outcomes","PLUTO","Inclusion Criteria:\n\n\\- Undergoing an elective, high-risk gastro-intestinal or vascular procedure, or intermediate risk procedure (including gynaecological, orthopaedic and head and neck surgery) if the procedure includes a laparotomy and\u002For is associated with a scheduled hospital length of stay ≥ 5 days.\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* Emergency surgery\n* Severe anaemia (Hb \\\u003C 4.5 mmol\u002FL)\n* Unable to provide informed consent",{"count":328,"type":21},9000,"1 Year","Purpose: with an increased risk of complications. Improved preoperative risk stratification and earlier diagnosis of these complications may ameliorate postoperative recovery and improve long-term outcomes. The perioperative longitudinal study of complications and long-term outcomes (PLUTO) aims to establish a comprehensive biorepository that will facilitate research in this field.\n\nPatients undergoing elective intermediate to high-risk non-cardiac surgery are eligible for enrolment. For the first 7 postoperative days (or longer as indicated), participants will be subjected to daily bedside visits by dedicated observers, who adjudicate clinical events and perform non-invasive physiological measurements (including handheld spirometry and single-channel EEG). In addition, we will collect blood samples as well as microbiome specimens at selected time points. Primary study outcomes are the postoperative occurrence of nosocomial infections, major adverse cardiac events, pulmonary complications, acute kidney injury and delirium. Secondary outcomes include mortality as well as long-term psychopathology, cognitive dysfunction, and quality of life.\n\nPLUTO is the first perioperative biobank worldwide that includes a broad range of high-risk surgical patients, collecting prospective bedside data as well as both blood and microbiome specimens during the entire perioperative period. The data and materials collected in PLUTO will be used to develop, externally validate, and update prognostic prediction models for improved risk assessment, to test novel biomarkers for early detection of postoperative complications and to study the aetiology, attributable morbidity and mortality related to these events.",[28,264,332,333,334],"Myocardium; Injury","Kidney Injury","Delirium","2023-11-28",{"date":337,"type":35},"2023-11-29",{"date":339,"type":35},"2020-02-21",{"date":341,"type":21},"2040-02-21",{"name":343,"class":95},"UMC Utrecht",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":357,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":43},"100510404","mitochondrial-function-in-the-peri-operative-setting-an-observational-study-100510404","NCT05925998","Mitochondrial Function in the Peri-operative Setting: an Observational Study","MITOSIS","Inclusion Criteria:\n\n* Aged 18 years or above.\n* Having elective major abdominal surgery under general anaesthesia requiring a CVC and arterial line.\n* Planned for a Total Intravenous Anaesthesia (TIVA) technique +\u002F- additional regional or neuraxial anaesthesia.\n* Admitted \\>6 hours prior to planned start of surgery as part of their normal care\n* Willingness to donate blood and breath samples to the study; declining muscle biopsy would not preclude inclusion.\n\nExclusion Criteria:\n\n* Currently pregnant or up to 6 weeks post-partum\n* Participating in an interventional research study concerning intra-operative management already\n* Lacks capacity to give consent to participate in the study at time of recruitment\n* Currently in custody\n* Surgery in the past 28 days\n* Existing primary mitochondrial disease as defined by previous genetic testing\u002F genome- or exome- sequencing results, or formal diagnosis by a medical professional",{"count":352,"type":21},50,"Complications after surgery are common and a burden for patients and health services. Therefore it is important that clinicians improve surgical outcomes. Mitochondria are the part of the body's cells that manage energy. Research has already shown that how our body's mitochondria behave can predict who survives in intensive care patients. The investigators think this could also predict who is more likely to develop complications after surgery. Therefore a study has been designed to find out if changes in mitochondria are related to postoperative complications. This will help doctors improve how they prepare patients for surgery and potentially how they manage their treatment, and result in improving outcomes for patients after surgery.\n\nThis study will recruit patients scheduled for major abdominal surgery as part of their treatment. The investigators will take samples of breath, blood and muscle to measure changes in mitochondria from the day before surgery to 7 days postoperatively. The muscle samples will only be taken when the patient is asleep having their operation. These samples will be used to analyse mitochondria. This study will be in two phases. Phase 1 is a pilot of up to 10 patients focussed on feasibility. Following this there will be an interim data analysis. The results may allow further optimisation to reduce the patient burden, eg reduction in sampling frequency, or avoiding need for muscle biopsy. The second phase will be a full cohort study of up to 40 patients, focussed on association of mitochondrial markers with clinical outcomes, such as postoperative complications, oxygen levels, pain, confusion and length of intensive care stay.\n\nThe results of this study could improve how doctors select and prepare patients for surgery. It may also affect how doctors manage their treatment during and after operations. This could result in reducing complications and illness burden for patients after surgery.",[355,28,356],"Mitochondrial","Surgery-Complications","NOT_YET_RECRUITING","2023-06-27",{"date":360,"type":35},"2023-07-03",{"date":362,"type":21},"2023-07-05",{"date":364,"type":21},"2026-08-01",{"name":366,"class":95},"University Hospital Southampton NHS Foundation Trust",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":157,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":375,"targetDuration":329,"studyType":53,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":357,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":43},"100506068","registry-of-anesthesia-and-perioperative-medicine-100506068","NCT05869578","Registry of Anesthesia and Perioperative Medicine","Registry of Patients Subjected to the Perioperative Care of the Anesthesia Service of Clinica Alemana of Santiago Chile","RAMP","Inclusion Criteria:\n\n* All individuals\n* Individuals agreeing to participate in the study by signing a consent\n\nExclusion Criteria:\n\n* The subjects who had insufficient data in their files",{"count":376,"type":21},10000,"To assess mortality and morbidity associated to anesthesia interventions",[28,379,380,381,382,383],"Perioperative\u002FPostoperative Complications","Anesthesia Morbidity","Anesthesia; Adverse Effect","Anesthesia Complication","Anesthesia; Reaction","2023-05-19",{"date":386,"type":35},"2023-05-22",{"date":388,"type":21},"2023-06-01",{"date":390,"type":21},"2045-01-01",{"name":392,"class":95},"Clinica Alemana de Santiago"]